Hartman Anne-Renee, Helft Paul
Menlo Park, CA 94025, USA.
Breast Cancer Res. 2007;9(2):103. doi: 10.1186/bcr1663.
The CYP2D6 gene is responsible for the majority of tamoxifen metabolism. Recent compelling, yet limited data have determined that postmenopausal women who carry a functional polymorphism in the CYP2D6 gene have a worse clinical outcome than women who have a wild-type genotype. In this commentary we discuss the level of evidence needed to change clinical practice and whether CYP2D6 genotyping is appropriate for all women considering tamoxifen as part of their adjuvant therapy.
CYP2D6基因负责大部分他莫昔芬的代谢。最近有令人信服但有限的数据表明，携带CYP2D6基因功能多态性的绝经后女性的临床结局比具有野生型基因型的女性更差。在这篇评论中，我们讨论了改变临床实践所需的证据水平，以及CYP2D6基因分型是否适用于所有考虑将他莫昔芬作为辅助治疗一部分的女性。
